Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin
M Benedikt, F Aziz, T Fröschl, C Strohhofer… - Scientific Reports, 2024 - nature.com
The EMMY trial was a multicentre, investigator-initiated, placebo-controlled, double-blind
trial, which enrolled 476 patients immediately following AMI and the first study demonstrating …
trial, which enrolled 476 patients immediately following AMI and the first study demonstrating …
The Year 2022 in Cardiovascular Diseases—Clinics and Practice
MG Abrignani - Clinics and Practice, 2023 - mdpi.com
This journal has recently achieved significant milestones, receiving its first impact factor of
2.3 and CiteScore of 2.0. Clinics and Practice is especially devoted to the clinical aspects of …
2.3 and CiteScore of 2.0. Clinics and Practice is especially devoted to the clinical aspects of …
[PDF][PDF] Antiarrhythmic Effect of SGLT-2 Inhibitors in High-degree AV Block Caused by Heart Failure: A Case Report
NARSN Putra, IK Susila - 2024 - e-journal.unair.ac.id
Background: According to WHO's Top 10 Global Health Threats, noncommunicable
diseases such as heart failure contribute to more than 70% of all deaths worldwide. Several …
diseases such as heart failure contribute to more than 70% of all deaths worldwide. Several …
[PDF][PDF] ЭКСПЕРИМЕНТАЛЬНАЯ ОЦЕНКА ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ ЭМПАГЛИФЛОЗИНА ПРИ ИШЕМИЧЕСКИХ ПОРАЖЕНИЯХ МИОКАРДА В …
ДЮ Ивкин - iemspb.ru
Основными причинами формирования хронической сердечной недостаточности (ХСН)
у пациентов в Российской Федерации являются артериальная гипертензия …
у пациентов в Российской Федерации являются артериальная гипертензия …
[引用][C] The electrocardiogram in heart failure trials: Missing in action
KP Anderson - European Journal of Heart Failure, 2024 - Wiley Online Library